Navigation Links
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
Date:3/6/2008

nticipated filing a supplemental New Drug Application for Renvela's use in non-dialysis patients during the first half of 2008. Given the current discussions with the FDA, it will not be necessary for the company to file an sNDA for this indication. However, Genzyme anticipates the Renvela label expansion will take place within a similar timeframe had it gone a more traditional route. During the second quarter, Genzyme also plans to file for U.S. approval of the powder formulation of the product, which may make it easier for patients to comply with their prescribed treatment program.

"We are very pleased with the progress we've made to date on our comprehensive global plan for Renvela," stated John P. Butler, president, Genzyme Renal. "The U.S. launch in dialysis, the E.U. and Brazil filings, and the positive nature of our current conversations with the FDA represent significant steps forward as we work to make this important product available to all patients who can benefit from it."

Renvela is a next-generation version of Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States. It is a calcium-free, metal-free, non-absorbed phosphate binder and is available in the U.S. as 800mg tablets. Renvela offers all of the advantages of Renagel with the benefit of a carbonate buffer. In a clinical study comparing Renvela to Renagel, both drugs controlled serum phosphorus equally to within KDOQI recommended ranges. Patients on Renvela, however, were more likely to maintain bicarbonate levels within the recommended KDOQI ranges, and had a lower incidence of gastrointestinal adverse events.

About Renagel and Renvela

Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate) both control serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Controlling serum phosphorus is an important element in the care of dialysis patients. Elevated serum phosphorus levels are common in dialysis
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
2. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
3. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
4. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
5. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
6. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
7. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
8. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
9. Genzyme Launches Cholestagel(R) in Europe
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... ANGELES , Feb. 26, 2015 Tauriga ... life sciences company with interests in the natural wellness ... technology, announced today that its products will be featured ... Roth Capital Partners, 27 th Annual Growth Stock ... Carlton, located at 1 Ritz Carlton Drive, ...
(Date:2/26/2015)... PHILADELPHIA , Feb. 26, 2015  Spark Therapeutics (NASDAQ: ... its management team will participate in the Cowen and ... at 9:40 a.m., Eastern, at the Boston Marriott Copley ... a Spark Therapeutics presentation from the Cowen conference, please ... Events" section of the Spark Therapeutics website at ...
(Date:2/26/2015)... , Feb. 26, 2015 Caris Life ... at the 2015 Genitourinary Cancers Symposium in ... clinical utility of tumor profiling. Both studies utilized ... profiling service, to identify biomarkers that shed light ... and small cell bladder cancer (SCBC). ...
(Date:2/25/2015)... , Feb. 25, 2015 truBrain ... is featured in this week,s Power Pitch segment ... to discuss the company,s traction and growth strategy, ... the crowd funding site CircleUp. The ... that are validated by neurotechnology, while also discussing ...
Breaking Biology Technology:SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2
... CRY ), a,biomaterials, medical device and tissue processing company, ... Annual Piper Jaffray Health,Care Conference at The New York Palace ... Anderson, president and chief executive officer of CryoLife,Inc., will provide ... 2:30 p.m. Eastern Time. , ...
... The Global Probiotics Council,(GPC), a committee formed ... the availability of two grants for the second ... Each Young,Investigator Grant will provide $50,000 over one ... role of probiotics and gastrointestinal microbiota in health,and ...
... Queen,s University Belfast is to become the United Kingdom,s ... ,cyber-attacks, after a funding boost from the Engineering and ... the EPSRC will help fund a new Innovation and ... (CSIT) - which will be based at Queen,s Institute ...
Cached Biology Technology:CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference 2New Young Investigator Grants for Probiotics Research Announced 2New Young Investigator Grants for Probiotics Research Announced 3New Young Investigator Grants for Probiotics Research Announced 4Queen's secures £25M for UK's cyber safety 2
(Date:2/24/2015)... 24, 2015 Research and Markets ... the "Global 2D Gesture Recognition Market 2015-2019" ... The analysts forecast the Global 2D Gesture Recognition ... over the period 2014-2019 The increased ... is one of the major trends in the ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... first time, scientists have shown that amniotic fluid (the ... new source of stem cells for therapeutic applications. The ... Blood , the official journal of the American ... other scientists, our research team wondered whether stem cells ...
... that its latest journal, Disease Models & Mechanisms ... MEDLINE. MEDLINE (http://www.pubmed.gov) is the premier bibliographic database of ... National Institutes of Health (NIH), MEDLINE contains over 16 million ... DMM has been recommended for inclusion by ...
... Md. (Mar. 31, 2009) Octogenarian women were unable to ... targeted at strengthening the thigh muscle, according to a ... . The results are surprising because previous studies have ... for people who are into their 70s. An increase ...
Cached Biology News:Amniotic fluid may provide new source of stem cells for future therapies 2Amniotic fluid may provide new source of stem cells for future therapies 3Disease Models & Mechanisms -- selected for indexing in Medline 2As good as it gets: Octogenarian muscles don't get stronger with exercise 2As good as it gets: Octogenarian muscles don't get stronger with exercise 3
Homo sapiens olfactomedin 1, transcript variant 3...
... agarose-digesting enzyme isolated from Pseudomonas atlantica. ... in agarose producing carbohydrate molecules that ... carbohydrate molecules will not interfere with ... Gelzyme enzyme can be used for ...
... the cellular components necessary for protein synthesis ... termination factors) but has not been treated ... primarily for the isolation of these components ... globin mRNA. Untreated Lysate is prepared from ...
...
Biology Products: